Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930586 | 0.95 | P2RX3 (0.71) | P2RX3P2RX2 | |
| SCHEMBL3928486 | 0.91 | P2RX3 (0.79) | P2RX3P2RX2 | |
| SCHEMBL1493863 | 0.87 | P2RX3 (0.78) | P2RX3P2RX2 | |
| SCHEMBL30215821 | 0.87 | P2RX3 (0.78) | P2RX3P2RX2 | |
| SCHEMBL3915992 | 0.84 | P2RX3 (0.61) | P2RX3P2RX2 | |
| SCHEMBL1494342 | 0.83 | P2RX3 (0.71) | P2RX3P2RX2 | |
| SCHEMBL30215764 | 0.83 | P2RX3 (0.71) | P2RX3P2RX2 | |
| SCHEMBL15478778 | 0.82 | P2RX3 (0.70) | P2RX3P2RX2 | |
| SCHEMBL3104191 | 0.81 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL3928472 | 0.81 | P2RX3 (0.75) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924564-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-11-09 | — | — | EP | claimed |
| EP-1924564-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-7531547-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1924564-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025899-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049758-A1 | Urogenital disorders; incotinence; analgesics; respiratory system disorders; gastrointestinal disorders; premenstrual tension | P2RX3, P2RX1, P2RX2 | P2RX3 1/4885P2RX2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.